MiMedx Scientific Study To Be Published In The International Wound Journal

MARIETTA, Ga., July 31, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "Biological Properties of Dehydrated Human Amnion/Chorion Grafts: Implications for Chronic Wound Healing" has been accepted for publication in the International Wound Journal.  The electronic publication of the study will be available in early August, and the hard copy is expected to be published in the December 2013 edition of the International Wound Journal.

To better understand the mechanisms responsible for the healing qualities of MiMedx dehydrated amnion/chorion membrane allografts (dHACM), the MiMedx research department, led by its Chief Scientific Officer, Thomas Koob, PhD, partnered with researchers from Stanford University School of Medicine and The Georgia Institute of Technology Biotechnology Complex.  Parker H. "Pete" Petit, Chairman and CEO, said, "Fundamentally, the researchers proved, among other things, that our allografts attract critically important regenerative stem cells to the wound site to help repair the wound. In effect, the research confirms that our proprietary PURION® processed allografts act as a "stem cell magnet." 

Bill Taylor, President and Chief Operating Officer, stated, "The research concluded that the MiMedx dHACM allografts positively affect at least four distinct physiological processes critical to wound healing, particularly in chronic wounds. dHACM modulates the inflammatory process, inhibits metalloproteinase activity and matrix degradation, induces regenerative cell proliferation and recruits stem cells. Clearly, multiple factors work in unison to have this kind of impact.  As opposed to a single therapeutic agent, dHACM allografts are a multifaceted, regenerative biomaterial that revitalizes wound healing."

"We will be submitting additional papers that delve deeper into the biological process of our 'stem cell magnet' allografts. These studies involve determining the source of the stem cells, establishing the angiogenic properties of dHACM, and gaining an in depth understanding of various mechanisms of action in wound healing," concluded Petit.

About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies, HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 160,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to the results to be reported in additional clinical publications. These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the results of additional publications will not chronicle, as anticipated, effectiveness of the Company's PURION® processed allografts, that the additional publications may not be released in the time period anticipated, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2012. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

SOURCE MiMedx Group, Inc.